Compile Data Set for Download or QSAR
Report error Found 50 Enz. Inhib. hit(s) with all data for entry = 10138
TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516578(US11053243, Example 189b | methyl [(2S)-1-{(2S)-2-...)
Affinity DataEC50:  0.00100nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516573(tert-butyl {(1R)-2-[(2S)-2-({4-[5-({[(2S)-1-{(2R)-...)
Affinity DataEC50:  0.00200nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50147212(CHEMBL3765311 | US11053243, Example 192)
Affinity DataEC50:  0.00200nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516583(US11053243, Example 203)
Affinity DataEC50:  0.00400nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516574(US11053243, Example 169 | tert-butyl {(1R)-2-[(2S)...)
Affinity DataEC50:  0.00400nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516552(US11053243, Example 94 | (2S,2'S)-N,N'-6,11-dihydr...)
Affinity DataEC50:  0.00600nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516568(tert-butyl {(1R)-2-[(2S)-2-({2- [4-({[(2S)-1-acety...)
Affinity DataEC50:  0.00900nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516584(US11053243, Example 213)
Affinity DataEC50:  0.00900nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516553(US11053243, Example 95 | (2S,2'S)-N,N'-5,6,7,12- t...)
Affinity DataEC50:  0.0100nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516563(US11053243, Example 119 | propan-2-yl [(1R)-2-oxo-...)
Affinity DataEC50:  0.0130nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516554(US11053243, Example 96 | N-(6,11-dihydro-5H- benzo...)
Affinity DataEC50:  0.0150nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516576(US11053243, Example 186 | tert-butyl {(1S)-2-[(2S)...)
Affinity DataEC50:  0.0150nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516564(tert-butyl [(1R)-2-{(2S)-2-[(2-{2-[(2S)-1-{(2R)-2-...)
Affinity DataEC50:  0.0160nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516546(US11053243, Example 45 | (2S)-1-[(2R)-2-phenyl-2- ...)
Affinity DataEC50:  0.0200nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516580(US11053243, Example 191)
Affinity DataEC50:  0.0200nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516543(US11053243, Example 40 | di-tert-butyl (1H,1′...)
Affinity DataEC50:  0.0260nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516556(US11053243, Example 100 | benzyl (2S)-2-[5-(4-{5-[...)
Affinity DataEC50:  0.0310nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516570(tert-butyl (2S)-2-[(3-fluoro-2-{4- [({(2S)-1-[(2R)...)
Affinity DataEC50:  0.0360nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516555(US11053243, Example 99 | tert-butyl {(1R)-2-[(2S)-...)
Affinity DataEC50:  0.0380nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516561(US11053243, Example 107 | tert-butyl {(1R)-2-[(2S)...)
Affinity DataEC50:  0.0400nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516538(US11053243, Example 15 | tert-butyl {(1R)-2-[(2S)-...)
Affinity DataEC50:  0.0450nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516544(US11053243, Example 41 | tert-butyl {(1R)-2-oxo-1-...)
Affinity DataEC50:  0.0500nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516582(US11053243, Example 193 | (2R)-2-(diethylamino)-1-...)
Affinity DataEC50:  0.0500nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516566(tert-butyl {(1S)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2S)...)
Affinity DataEC50:  0.0500nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516540(US11053243, Example 26 | (2S)-1-[(2R)-2-(diethylam...)
Affinity DataEC50:  0.0630nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516562(US11053243, Example 116 | N-(methoxycarbonyl)-L-va...)
Affinity DataEC50:  0.0650nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516579(US11053243, Example 190)
Affinity DataEC50:  0.0670nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516550(US11053243, Example 62 | (2S)-1-[(2R)-2-(diethylam...)
Affinity DataEC50:  0.0670nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516547(US11053243, Example 49 | (2S)-1-(2,3-diphenylpropa...)
Affinity DataEC50:  0.0720nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516560(US11053243, Example 105 | tert-butyl{(1R)-2-[(2S)-...)
Affinity DataEC50:  0.0800nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516549(US11053243, Example 60 | (2S)-1-[(2R)-2phenyl-2- (...)
Affinity DataEC50:  0.130nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516577(US11053243, Example 189a | methyl [(2S)-1-{(2S)-2-...)
Affinity DataEC50:  0.150nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516551(US11053243, Example 72 | (2S)-1-[(2R)-2-(dimethyla...)
Affinity DataEC50:  0.170nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516542(US11053243, Example 39 | (2S,2′S) N,N′...)
Affinity DataEC50:  0.240nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516572(tert-butyl {(1R)-2-[(2S)-2-({4-[5-({[(2S)-1-{(2R)-...)
Affinity DataEC50:  0.5nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516557(US11053243, Example 101 | 1-[(2R)-2-(dimethylamino...)
Affinity DataEC50:  0.5nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516565((2S)-N-{4-[3-fluoro-5-({[(2S)-1- (phenylacetyl)pyr...)
Affinity DataEC50:  0.700nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516571((2S) N-{4-[3-cyano-5-({[(2S)-1-(phenylacetyl)pyrro...)
Affinity DataEC50:  0.900nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516548(US11053243, Example 58 | N-{2-[4-(acetylamino)phen...)
Affinity DataEC50:  0.970nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516559(US11053243, Example 103 | 1-[(2S)-2-(dimethylamino...)
Affinity DataEC50:  5.70nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516558(US11053243, Example 102 | tert-butyl {(1R)-2-[(2S)...)
Affinity DataEC50:  8.30nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516569(tert-butyl {(1R)-2-[(2S)-2-({3- fluoro-2-[4-(2-oxo...)
Affinity DataEC50:  8.5nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516377(US11053243, Example 2 | (2S)-1-(phenylacetyl)- N-{...)
Affinity DataEC50:  9nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516537(US11053243, Example 14 | tert-butyl {(1S)-2-[(2S)-...)
Affinity DataEC50:  10nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516545(US11053243, Example 42 | (2S)-1-(phenylacetyl)-N-{...)
Affinity DataEC50:  14nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516567(tert-butyl {(1S)-2-[(2S)-2-({2-[4- (acetylamino)ph...)
Affinity DataEC50:  17nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516539(US11053243, Example 19 | N-{2-[4-(acetylamino)phen...)
Affinity DataEC50:  25nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516541(US11053243, Example 30 | N-{2-[4-(acetylamino)phen...)
Affinity DataEC50:  26nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516378(US11053243, Example 6 | (2S) N-{3-chloro-2-[4-({[(...)
Affinity DataEC50:  200nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetGenome polyprotein(HCV)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM516575(US11053243, Example 178 | tert-butyl {(1R)-2-[(2S)...)
Affinity DataEC50:  317nMAssay Description:Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent